Top

Published in:

01-09-2008 | Research Paper

A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1

Authors: Munehisa Takahashi, Mutsuo Furihata, Nobuyoshi Akimitsu, Morihiro Watanabe, Sunil Kaul, Noboru Yumoto, Tomoko Okada

Published in: Clinical & Experimental Metastasis | Issue 5/2008

Abstract

To understand the mechanisms underlying bone marrow metastasis precisely, we established the highly metastatic 4T1E/M3 murine breast cancer cell line. 4T1 murine breast cancer cells were transfected with the neomycin resistance gene, selected in G418, intravenously injected into mice, and harvested from bone marrow. By repeating this protocol three times, we established the 4T1E/M3 cells. The clonality of 4T1E/M3 cells was markedly high confirmed by genomic southern analysis using neo-gene probe. When tissues harvested from mice after intravenous injection of 4T1E/M3 cells were examined histologically, markedly enhanced bone marrow metastasis was observed; 77% of spines from 4T1E/M3-injected mouse showed metastasis as compared to 14% metastasis seen with the parent cells. In vitro, 4T1E/M3 cells attached more strongly to the plastic plate and to bone marrow-derived endothelial cells. DNA micro arrays, real time RT-PCR and FACS analyses revealed that the expression of ICAM-1 and β2 integrin was upregulated in 4T1E/M3 cells at both the mRNA and cell surface protein levels. 4T1E/M3 cells also showed greater anchorage-independent proliferation in soft agar, and migrated markedly faster than the parent cells in wound healing assays. Anti-ICAM-1 antibodies strongly inhibited both the colony formation and the migration activity of 4T1E/M3 suggesting the importance of the role of ICAM-1. Our newly established highly metastatic 4T1E/M3 cells may provide a potentially powerful tool to study the molecular mechanisms of bone marrow metastasis and to identify new molecular targets for therapeutic interventions.

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593PubMedCrossRef

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Bellahcene A, Bachelier R, Detry C et al (2007) Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 101:135–148PubMedCrossRef

Peyruchaud O, Winding B, Pecheur I et al (2001) Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 16:2027–2034PubMedCrossRef

Yoneda T, Williams PJ, Hiraga T et al (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16:1486–1495PubMedCrossRef

Bandyopadhyay A, Elkahloun A, Baysa SJ et al (2005) Development and gene expression profiling of a metastatic variant of the human breast cancer MDA-MB-435 cells. Cancer Biol Ther 4:168–174PubMed

Bandyopadhyay A, Agyin JK, Wang L et al (2006) Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 66:6714–6721PubMedCrossRef

Sheridan C, Kishimoto H, Fuchs RK et al (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59PubMedCrossRef

Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411:375–379PubMedCrossRef

10.

Luo Y, Zhou H, Krueger J et al (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116:2132–2141PubMedCrossRef

11.

Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263–266PubMedCrossRef

12.

Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399–1405PubMed

13.

Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58:1486–1493PubMed

14.

Pulaski BA, Terman DS, Khan S et al (2000) Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 60:2710–2715PubMed

15.

Monzavi-Karbassi B, Artaud C, Jousheghany F et al (2005) Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J Immunol 174:7057–7065PubMed

16.

Lewis JD, Shearer MH, Kennedy RC et al (2005) Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases. Cancer Res 65:2938–2946PubMedCrossRef

17.

Demaria S, Kawashima N, Yang AM et al (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11:728–734PubMed

18.

Brilliant MH, Gondo Y, Eicher EM (1991) Direct molecular identification of the mouse pink-eyed unstable mutation by genome scanning. Science 252:566–569PubMedCrossRef

19.

Tominaga H, Ishiyama M, Ohseto F et al (1999) A Water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun 36:47–50CrossRef

20.

Carmichael J, DeGraff WG, Gazdar AF et al (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942PubMed

21.

Okada T, Li J, Kodaka M et al (1998) Enhancement of type IV collagenases by highly metastatic variants of HT1080 fibrosarcoma cells established by a transendothelial invasion system in vitro. Clin Exp Metastasis 16:267–274PubMedCrossRef

22.

Palmieri D, Halverson DO, Ouatas T et al (2005) Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 97:632–642PubMedCrossRef

23.

Okada T, Akikusa S, Okuno H et al (2003) Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metastasis 20:639–646PubMedCrossRef

24.

Ohta H, Hamada J-I, Tada M et al (2006) HOXD3-overexpression increases integrin αvβ3 expression and deprives E-cadherin while it enhances cell motility in A549 cells. Clin Exp Metastasis 23:381–390PubMedCrossRef

25.

Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sPubMedCrossRef

26.

Pulaski BA, Clements VK, Pipeling MR et al (2000) Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother 49:34–45PubMedCrossRef

27.

Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518–524PubMedCrossRef

28.

Waghorne C, Thomas M, Lagarde A et al (1988) Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res 48:6109–6114PubMed

29.

Frost P, Kerbel RS, Hunt B et al (1987) Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2′-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression. Cancer Res 47:2690–2695PubMed

30.

Eckhardt BL, Parker BS, van Laar RK et al (2005) Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 3:1–13PubMed

31.

Irshad S, Pedley RB, Anderson J et al (2004) The Brn-3β transcription factor regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo. J Biol Chem 279:21617–21627PubMedCrossRef

32.

Lee JY, Kim H, Ryu CH et al (2004) Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity. J Biol Chem 279:30265–30273PubMedCrossRef

33.

Muraoka-Cook RS, Kurokawa H, Koh Y et al (2004) Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64:9002–9011PubMedCrossRef

34.

Glondu M, Liaudet-Coopman E, Derocq D et al (2002) Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 21:5127–5134PubMedCrossRef

35.

Morimoto-Tomita M, Ohashi Y, Matsubara A et al (2005) Mouse colon carcinoma cells established for high incidence of experimental hepatic metastasis exhibit accelerated and anchorage-independent growth. Clin Exp Metastasis 22:513–521PubMedCrossRef

36.

Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679–695PubMedCrossRef

37.

Hu J, Verkman AS (2006) Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J 20:1892–1894PubMedCrossRef

38.

Chen X, Lin J, Kanekura T et al (2006) A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res 66:11323–11330PubMedCrossRef

39.

Galaup A, Cazes A, Le Jan S et al (2006) Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 103:18721–18726PubMedCrossRef

40.

Rosette C, Roth RB, Oeth P et al (2005) Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26:943–950PubMedCrossRef

41.

Wang S, Coleman EJ, Pop LM et al (2006) Effect of an anti-CD54 (ICAM-1) monoclonal antibody (UV3) on the growth of human uveal melanoma cells transplanted heterotopically and orthotopically in SCID mice. Int J Cancer 118:932–941PubMedCrossRef

42.

Fanales-Belasio E, Zambruno G, Cavani A, Girolomoni G (1997) Antibodies against sialophorin (CD43) enhance the capacity of dendritic cells to cluster and activate T lymphocytes. J Immunol 159:2203–2211PubMed

43.

Rosenstein Y, Park JK, Hahn WC et al (1991) CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature 354:233–235PubMedCrossRef

44.

Ziprin P, Alkhamesi NA, Ridgway PF, Pech DH, Darzi AW (2004) Tumor-expressed CD43 (sialophorin) mediates tumour-mesothelial cell adhesion. Biol Chem 385:755–761PubMedCrossRef

45.

Kadaja-Saarepuu L, Laos S, Jããger K et al (2007) CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in non-hematopoietic cancer cell lacking the tumor suppressors p53 or ARF. Oncogene (advance online publication). doi:10.1038/sj.onc.1210802

Title: A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1
Authors: Munehisa Takahashi
Mutsuo Furihata
Nobuyoshi Akimitsu
Morihiro Watanabe
Sunil Kaul
Noboru Yumoto
Tomoko Okada
Publication date: 01-09-2008
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-008-9163-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer

Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition

Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis

Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity

TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression

SOD derivatives prevent metastatic tumor growth aggravated by tumor removal

Keynote webinar | Spotlight on antibody–drug conjugates in cancer